Cardiovascular
Hansen Medical to Exhibit Magellan Robotic System at 2013 Vascular Annual Meeting of the Society for Vascular Surgery
May 23, 2013 4:03 pm | by The Associated Press | News | CommentsHansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it will exhibit its Magellan Robotic System at the 2013 Vascular Annual Meeting® of the Society for Vascular Surgery from May 30 - June 1 at the Moscone West Convention Center in San...
Cardiovascular Systems Presents New Late-Breaking Coronary Results at EuroPCR Conference
May 23, 2013 10:00 am | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 23, 2013--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), presented 30-day results from its ORBIT II study of coronary artery disease in a late-breaking presentation at the 2013 European Association of Percutaneous Cardiovascular Interventions (EuroPCR)...
Medtronic Completes Enrollment in Landmark U.S. Study of Symplicity Renal Denervation System for Treatment-Resistant Hypertension
May 23, 2013 6:06 am | by The Associated Press | News | CommentsMedtronic, Inc., today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity renal denervation system for treatment-resistant hypertension. Renal denervation is a minimally invasive, catheter-based procedure to reduce activity of the renal (kidney) nerves, which are part of the sympathetic nervous system and help regulate blood pressure.
InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
May 23, 2013 6:00 am | by PR Newswire | News | CommentsInspireMD, Inc., the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients.
Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013
May 23, 2013 4:30 am | by PR Newswire | News | CommentsSAN DIEGO and PARIS, May 23, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced preliminary...
One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology
May 23, 2013 4:15 am | by The Associated Press | News | CommentsST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 23, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that the company’s EnligHTN ™ Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after...
New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix™ Renal Denervation System
May 22, 2013 12:20 pm | by PR Newswire | News | CommentsPARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix™ Renal Denervation...
CardioKinetix Announces Positive Clinical Data Showing Consistent Compelling Positive Results for Patients Treated with Minimally Invasive Structural Heart Device for Heart Failure
May 22, 2013 11:00 am | by The Associated Press | News | CommentsPARIS & MENLO PARK, Calif.--(BUSINESS WIRE)--May 22, 2013--CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced results of a meta-analysis study of the first-of-its-kind catheter-based Parachute ® Ventricular Partitioning Device....
BioVentrix to Exhibit Revivent™ System, which Surpasses Survival Benefit Threshold for Heart Failure Treatment, at European Heart Failure Congress
May 22, 2013 8:30 am | by The Associated Press | News | CommentsLISBON, Portugal--(BUSINESS WIRE)--May 22, 2013--BioVentrix, pioneer of the Less Invasive Ventricular Enhancement™ (LIVE™) procedure for the treatment of heart failure (HF), announced today that it will showcase its Revivent™ Myocardial Anchoring System at the European Heart Failure Congress (HFC)...
St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice Session
May 21, 2013 9:52 am | by The Associated Press | News | CommentsST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 21, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the start of its landmark EnligHTNment clinical study. This is the largest randomized, prospective trial to determine whether renal denervation and...
Economic Model of the Life-time Cost Impact of Heart Valve Prosthetic Choice to be Presented at ISPOR Meeting
May 21, 2013 9:00 am | by The Associated Press | News | CommentsAUSTIN, Texas--(BUSINESS WIRE)--May 21, 2013--On-X® Life Technologies, Inc. (On-X LTI) announced today that a cost analysis entitled, “Initial Heart Valve Replacement Prosthetic Choice Has Long-Term Complications and Cost Impact: A Comparative Analysis,” will be presented in poster form at the...
MAQUET Cardiovascular Acquires LAAx Inc. and Its TigerPaw System II Occlusion Device to Expand Cardiac Surgery Offering
May 21, 2013 8:00 am | by The Associated Press | News | CommentsMAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has acquired LAAx Inc., a privately held company that has developed a unique mechanical occlusion device called the TigerPaw@ System II ("TigerPaw II"). When implanted, TigerPaw II safely and...
VerrataT Pressure Guide Wire and iFR@ (Instant Wave-Free RatioT) Software Modality will be on display at EuroPCR 2013[1]
May 21, 2013 4:40 am | by The Associated Press | News | CommentsVolcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will demonstrate the VerrataT Pressure Guide Wire and the iFR@ (Instant...
Medtronic Finds TAVI with CoreValve System Cost Effective for Treating Patients with Severe Aortic Stenosis
May 21, 2013 4:06 am | by The Associated Press | News | CommentsFocused on offering devices that provide both clinical and economic value, Medtronic, Inc. unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation with the CoreValve System to medical management. Presented at EuroPCR 2013, the United Kingdom-based analysis compared the "real world" Medtronic CoreValve ADVANCE study to the medical management cohort of the PARTNER B study.
New Diagnostics Solutions from Welch Allyn to Help Improve Patient Safety, Reduce Risk for Facilities
May 20, 2013 11:05 am | by Welch Allyn | News | CommentsWelch Allyn, a leading medical diagnostic device company that specializes in helping clinicians improve patient outcomes, will showcase its new FlexiPort® EcoCuffTM blood pressure cuff and EarlySense Vitals Surveillance System at the National Teaching Institute & Critical Care Exposition this week at the Boston Convention & Exhibition Center in Boston, Mass.
Biosensors Receives CE Mark Approval for BioMatrix NeoFlex
May 20, 2013 10:54 am | by Biosensors International | News | CommentsBioMatrix NeoFlex features a new advanced stent delivery system, improving pushability, trackability, and crossability. It also has a lower lesion entry profile than its predecessor. BioMatrix NeoFlex retains the same combination of abluminal biodegradable polymer coating, proprietary limus drug Biolimus A9, and platform that has made the BioMatrix stent family an increasingly popular choice of DES in global markets where available.
CardioDx Announces Publication of the IMPACT-CARD Trial Demonstrating Use of Corus@ CAD Test Influenced Cardiologists' Clinical Management of Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease
May 20, 2013 8:31 am | by The Associated Press | News | CommentsCardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the publication of the IMPACT-CARD (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) trial in Critical Pathways in Cardiology. This prospective...
Medtronic Receives 'CE' Mark for 'Export Advance' Aspiration Catheter
May 20, 2013 7:06 am | by The Associated Press | News | CommentsExpanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) announced today that the Export Advance aspiration catheter recently received the CE (Conformité Européenne) mark and will soon be launched in Europe and other international markets.
OrbusNeich's GenousT Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
May 20, 2013 5:00 am | by The Associated Press | News | CommentsOrbusNeich today announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an...
Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
May 19, 2013 1:43 pm | by Bio-Medicine.Org | News | CommentsSANTA ROSA, Calif. , May 20, 2013 /- Claret Medical, Inc. announced the publication of an original manuscript by Dr. Nicolas Van Mieghem et al., Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve Replacement . Published ahead of print in Circulation, May 7 th this research is the result of a collaboration between Erasmus Medical Center, Rotterdam,
Statistical Challenges in Medical Device Trail Evaluation
May 17, 2013 4:30 pm | by The Associated Press | News | CommentsMedical devices are any medical items that are neither a drug nor a biological product. In light of their different mechanisms, actions and regulatory requirements, medical device (MD) trail evaluations are much more complicated than drug trails due to their unique clinical practices....
Alumina Substrate and Medical Equipment Resistors
May 17, 2013 4:13 pm | by Michael West, Director of Engineering, Ohmite Manufacturing | Articles | CommentsThis article will walk through the various characteristics of these resistors, including high resistance values, high voltage handling, small size, resiliency, and more, to demonstrate how they might aid in the design of medical devices.
Security Risks Found in Sensors for Heart Devices
May 17, 2013 12:13 pm | by University of Michigan | News | CommentsThe type of sensors that pick up the rhythm of a beating heart in implanted cardiac defibrillators and pacemakers are vulnerable to tampering, according to a new study conducted in controlled laboratory conditions. Implantable defibrillators monitor the heart for irregular beating and, when necessary, administer an electric shock to bring it back into normal rhythm.
Diagnosing Heart Attacks: There's an App for That
May 17, 2013 11:42 am | by American Heart Association | News | CommentsAn experimental, inexpensive iPhone application transmitted diagnostic heart images faster and more reliably than emailing photo images, according to a research study presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2013.
CardioDx Announces New Data Demonstrating Use of Corus® CAD in the Primary Care Setting for Evaluation of Symptomatic Patients with Suspected CAD Influences Clinical Decision Making
May 17, 2013 11:00 am | by PR Newswire | News | CommentsPALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced results of a clinical utility study of the Corus® CAD gene expression test in the real-world primary care setting for evaluating patients with...
